Blueprint Medicines (BPMC) Tops Q4 EPS by 34c

Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.35), $0.34 better than the analyst estimate of ($1.69). Revenue for the quarter came in at $51.5 million versus the consensus estimate of $26.07 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target